Since several lines of evidence suggested that the SP142 assay detects more immune cells but fewer tumor cells compared to other PD-L1 assays [46, 47], and thus it is expected that SP142-positive TNBCs would be enriched with TILs, CD8+ cells, and other immune features, and they were. This evidence concerns the gene CD274 and neoplasm.